External Validation of Current Quality Care Metrics after Radical Nephroureterectomy

The assessment of surgical quality in uro-oncology has evolved significantly with the emergence of composite outcome metrics. Two such models—the tetrafecta and pentafecta—have been proposed following radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), but until now, neither had undergone external validation in an independent cohort.^1,2

Our multicenter retrospective study included 545 patients who underwent radical nephroureterectomy (RNU) for localized upper tract urothelial carcinoma (UTUC) between 2012 and 2023.

Tetrafecta was defined by the achievement of four criteria:

Negative soft tissue surgical margins,
Bladder cuff excision,
Lymph node dissection in accordance with guideline recommendations, and
Absence of any recurrence within 12 months postoperatively.

Pentafecta, on the other hand, was based on five components:

Negative surgical margin,
Complete bladder cuff resection,
Absence of hematologic complications (e.g., transfusion or thromboembolic events),
Absence of major complications (Clavien-Dindo ≥ 3), and
Absence of 12-month postoperative recurrence.

In this real-world cohort, 29.5% of patients achieved the tetrafecta and 34.5% met the pentafecta criteria, slightly lower than rates reported in development cohorts (33–53%), likely due to a higher proportion of patients with advanced-stage disease (over one-third were pT3 or higher).^1-3

Despite this, achieving either endpoint was significantly associated with improved oncological outcomes. Three-year overall survival (OS) was 90.1% for tetrafecta achievers versus 74.2% for non-achievers (p < 0.001), and 89.4% versus 73.4% for pentafecta (p < 0.001). Similarly, recurrence-free survival (RFS) was significantly better among those meeting tetrafecta (84.5%) or pentafecta (83.5%) criteria compared to others (57.6% and 56%, respectively; all p < 0.001). In multivariable analysis, only the pentafecta remained independently associated with improved OS (HR 0.30) and cancer-specific survival (HR 0.24).

Surgical approach played a notable role: open RNU was associated with higher rates of both tetrafecta (43.9% vs. 22.2%) and pentafecta (48.1% vs. 27.6%) compared to laparoscopic or robotic-assisted approaches. While laparoscopy yielded more frequent negative margins and fewer hematologic complications, open surgery led to more consistent bladder cuff resection and fewer early recurrences.

External validation demonstrated excellent predictive accuracy and calibration, with AUCs for 3-year OS of 0.92 (tetrafecta) and 0.93 (pentafecta), and for cancer-specific survival, 0.944 and 0.945, respectively. These results support Pentafecta as a robust and clinically relevant standard, particularly in high-risk UTUC populations.

Quality Metrics Are Useful — But Not Absolute

These quality indicators offer a structured approach to identifying targets for improvement. They support critical self-assessment of surgical performance, refine decision-making regarding operative strategies, and may help tailor adjuvant therapy. For a rare and heterogeneous disease, such metrics also offer an opportunity to document institutional expertise.

That said, no metric is without limitations. Composite endpoints like tetrafecta and pentafecta must not be misinterpreted as performance scores or used uncritically in comparative analyses. Their use in ranking institutions or specialists may lead to unintended consequences: avoidance of high-risk cases, distorted documentation, or oversimplification of surgical quality. Their true value lies in structured introspection, not competition.

In conclusion, while the pentafecta appears to be a robust and reproducible metric associated with meaningful survival benefits, it should be used thoughtfully, contextually, and always in service of patient-centered care.

Written by: Igor Duquesne, MD, MSc

Department of Urology, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France.
Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.

References:

Read the Abstract

Login